Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amylin’s SymlinPen To Launch In December

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."

You may also be interested in...



Amylin CEO: Firm Can Do Better With Byetta

Diabetes drug so far has failed to catch on with primary-care docs.

Amylin CEO: Firm Can Do Better With Byetta

Diabetes drug so far has failed to catch on with primary-care docs.

Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial

Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel